---
title: "Esperion (ESPR) was downgraded to a Hold Rating at Needham"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285108916.md"
description: "Esperion (ESPR) has been downgraded to a Hold rating by Needham analyst Serge Belanger, who set a price target of $3.22. Belanger, a 5-star analyst with a 12.8% average return and 49.40% success rate, focuses on the Healthcare sector. The current analyst consensus for Esperion remains a Hold."
datetime: "2026-05-04T19:05:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285108916.md)
  - [en](https://longbridge.com/en/news/285108916.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285108916.md)
---

# Esperion (ESPR) was downgraded to a Hold Rating at Needham

Esperion received a Hold rating and price target from Needham analyst Serge Belanger today.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Belanger is a 5-star analyst with an average return of 12.8% and a 49.40% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Esperion, Viridian Therapeutics, and Cormedix.

Currently, the analyst consensus on Esperion is a Hold with an average price target of $3.22.

### Related Stocks

- [ESPR.US](https://longbridge.com/en/quote/ESPR.US.md)
- [VRDN.US](https://longbridge.com/en/quote/VRDN.US.md)
- [CRMD.US](https://longbridge.com/en/quote/CRMD.US.md)

## Related News & Research

- [Key facts: Esperion Expands 2024–25 Programs; Estimates Fall 781.6%](https://longbridge.com/en/news/285820903.md)
- [Esperion Therapeutics’ 10-Q Forward-Looking Statements Highlight Significant Uncertainty and Investor Risk](https://longbridge.com/en/news/285830726.md)
- [Why Needham Analysts Think Cerebras Stock Can Gain Another 25% After Historic IPO](https://longbridge.com/en/news/289219447.md)
- [As tech stocks slide, the healthcare sector shines. Why some experts say they like this defensive play](https://longbridge.com/en/news/289242691.md)
- [H.C. Wainwright Sticks to Its Buy Rating for Shattuck Labs (STTK)](https://longbridge.com/en/news/289068921.md)